AMSTERDAM & BRUSSELS & LISBON & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Euronext, the leading pan-European exchange in the Eurozone, today announced trading volumes for November 2017.
In November 2017, the average daily transaction value on the Euronext cash order book stood at €8,141 million, up +11.0% compared to November 2016 and up +13.5% from the previous month. The average daily transaction value on ETFs was €481 million, down -22.1% compared to November 2016 and up +21.6% from the previous month. Euronext’s ETF offering slightly decreased this month to 828 listings at the end of November, compared to 831 at the end of the previous month. As a reminder, 790 ETFs were listed on Euronext markets at the end of 2016.
In November 2017, the overall average daily volume on derivatives reached 629,767 contracts, up +15.9% compared to November 2016 and up +26.5% compared to the previous month. In details,
- the average daily volume on equity index derivatives reached 219,503 contracts, down -7.0% compared to November 2016 and +14.5% from the previous month,
- the average daily volume on individual equity derivatives reached 350,175 contracts in November 2017, up +37.0% compared to November 2016 and +32.1% from the previous month,
- the average daily volume on commodities derivatives reached 60,089 contracts, up +16.6% compared to November 2016 and +46.9% from the previous month.
On a year-to-date basis, at end of November 2017, the overall average daily volume on Euronext derivatives stands at 551,326 contracts (+11.9% compared to end of November 2016) and the open interest was up at 19,727,262 contracts (+17.8% compared to end of November 2016).
FX spot trading
The average daily volume on the spot foreign exchange market of FastMatch, of which Euronext owns 90% of the capital since August 2017, stood at $17,777 million, up +3.9% compared to November 2016 and down -1.4% from the previous month.
In November 2017, Euronext had one technical listing, Reinet Investments on Euronext Amsterdam. In addition, €3.3 billion were raised on Euronext in corporate bonds and €2.0 billion of follow-on equity, including Eurofins Scientific €299m private placement and Erytech Pharma €107m capital increase.
Please refer to appendix tables for more details.
Appendix Tables: Euronext Cash Markets Monthly Activity; Euronext Derivatives Monthly Activity; FastMatch Monthly Activity.
About Euronext – www.euronext.com
Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.5 trillion in market capitalisation as of end June 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.
This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.
© 2017, Euronext N.V. - All rights reserved.